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Glutamate transport through astrocytic excitatory amino-acid transporters (EAAT)-1 and
EAAT-2 is paramount for neural homeostasis. EAAT-1 has been reported in secreted
extracellular microvesicles (eMV, such as exosomes) and because the protein kinase C
(PKC) family controls the sub-cellular distribution of EAATs, we have explored whether
PKCs drive EAATs into eMV. Using rat primary astrocytes, confocal immunoﬂuorescence
and ultracentrifugation on sucrose gradient we here report that PKC activation by
phorbol myristate acetate (PMA) reorganizes EAAT-1 distribution and reduces functional
[3H]-aspartate reuptake.Western-blots show that EAAT-1 is present in eMV from astrocyte
conditionedmedium, together with NaKATPase and glutamine synthetase all being further
increased after PMA treatment. However, nanoparticle tracking analysis reveals that PKC
activation did not change particle concentration. Functional analysis indicates that eMV
have the capacity to reuptake [3H]-aspartate. In vivo, we demonstrate that spinal astrocytic
reaction induced by peripheral nerve lesion (spared nerve injury, SNI) is associated with
a phosphorylation of PKC δ together with a shift of EAAT distribution ipsilaterally. Ex vivo,
spinal explants from SNI rats release eMV with an increased content of NaK ATPase,
EAAT-1 and EAAT-2. These data indicate PKC and cell activation as important regulators
of EAAT-1 incorporation in eMV, and raise the possibility that microvesicular EAAT-1 may
exert extracellular functions. Beyond a putative role in neuropathic pain, this phenomenon
may be important for understanding neural homeostasis and a wide range of neurological
diseases associated with astrocytic reaction as well as non-neurological diseases linked to
eMV release.
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INTRODUCTION
Among aplethora of functions, astrocytes (themost abundant cells
in the central nervous system) scavenge extracellular glutamate
through membrane excitatory amino-acid transporters (EAAT-
1 and EAAT-2). This reuptake is vital for neurotransmission
(Danbolt, 2001). Decay or hyperfunction of the reuptake machin-
ery have been identiﬁed or hypothesized in many neurological
conditions as diverse as epilepsy, ataxia, amyotrophic lateral scle-
rosis, ischemia, schizophrenia, or neuropathic pain and their
experimental models (Sung et al., 2003; Jen et al., 2005; Beart and
O’Shea, 2007; Daemen et al., 2008; Chao et al., 2010; Gosselin et al.,
2010b; Mirzaei et al., 2010). The current theory posits that the rate
of transporter synthesis is not sufﬁcient for EAAT regulation. The
correct and stable anchoring of these transporters at the plasma
membrane is a crucial modulation as well, in which the protein
kinase C (PKC) family is deemed important (Susarla et al., 2004;
Sheldon et al., 2008; Susarla and Robinson, 2008).
In addition to being present at the plasma membrane,
EAATs have been shown recently to occur in extracellu-
lar microvesicles (eMV; Faure et al., 2006). These organelles
of 40–1000 nm diameters may originate from intracellular
compartments belonging to late endosomes and multivesicular
bodies (these eMV are called exosomes, 40–100 nm) or from bud-
ding of plasma membrane (these eMV are referred to as shedding
microvesicles, 100–1000 nm). Exosomes and shedding microvesi-
cles have been found in virtually all investigated biological ﬂuids
and conditioned media. Microvesicles contain collections of pro-
teins, RNA and lipids, which are highly conserved across cell
types and listed in an online database (Mathivanan et al., 2012).
The current theories posit that eMV are important cell-to-cell
carriers for intercellular signaling molecules. Nevertheless, in
spite of their possible biological importance, research on eMV
is in its infancy with very little light shed on their regulation
either in homeostasis or in pathology. In particular, the iden-
tiﬁcation of intracellular signals that govern the sorting of a
speciﬁc cargo protein to eMV is largely unresolved. Remark-
ably, although eMV have been classically considered important
in the immune system and in tumor cells (Thery et al., 2009),
they are now regarded as pleiotropic in cell-to-cell communi-
cation (Kharaziha et al., 2012) including in the nervous system
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where virtually all cell populations produce eMV (Fruhbeis et al.,
2012).
The present study was therefore designed to address a twofold
question. First, using primary cultures of rat astrocytes, we
explored whether PKC activation regulates EAAT targeting to
eMV. Second, using a model of spinal astrogliosis induced by
peripheral nerve lesion we explored the possible deregulation
of EAAT subcellular distribution and enrichment in eMV. Our
results show that eMV from astrocytes contain functional EAAT-1
and that PKC activation results in a subcellular reorganization of
EAAT-1 together with an enrichment of this same transporter in
secreted eMV. Finally, in vivo, we conﬁrm that spinal astrogliosis
induced by peripheral nerve injury is associated with PKC activa-
tion, changes in EAAT-1 subcellular distribution (readdressing) as
well as EAAT-1 and EAAT-2 enrichment into eMV.
MATERIALS AND METHODS
CULTURE OF PRIMARY ASTROCYTES AND MICROGLIA
Full cortical astrocytic cultureswere used, according to themethod
of McCarthy with minor modiﬁcations (McCarthy and de Vellis,
1980, to maximize the yield of collected cells, thus minimizing
the number of needed animals). Cerebral cortices from 2 day old
Sprague Dawley rat pups were homogenized by mechanical trit-
uration and seeded onto poly-D-lysine coated 75 cm2 ﬂasks in
Dulbecco’s modiﬁed eagle medium (DMEM) glutamax (Invitro-
gen, USA), 10% normal calf serum with penicillin/streptomycin
(Invitrogen, USA). Cells were grown in a humidiﬁed 95% CO2
incubator at 37◦C.At conﬂuence, ﬂaskswere shaken at 250 rpm for
2 h. Detached microglia were seeded in coated 6-well microplates
in culture medium supplemented with 30% astrocyte conditioned
medium. Post-shaking adherent astrocytes were trypsinized and
seeded at 50% conﬂuence onto coated 6 or 24-well microplates or
coverslips. Two days later, astrocytes were differentiated (culture
medium, 2% normal calf serum, 150 μM dbcAMP, Sigma-
Aldricht, USA) for 5 days. Pharmacological compounds were
phorbol myristate acetate (PMA,ﬁnal concentration 1 μM,Sigma,
USA), Chelerythrine (CHE; 10 μM, 5 min pretreatment prior
to PMA, Tocris, USA) or vehicle (1% DMSO in PBS, 5 min
pretreatment prior to PMA).
ANIMALS AND SURGERY
All procedures were approved by theCommittee onAnimal Exper-
imentation for the canton of Vaud, Switzerland, in line with the
Swiss Federal Law on Animal Welfare and the recommendations
of the International Association for the Study of Pain. Spared
nerve injury (SNI) was performed on male Sprague Dawley rats
(Charler River, France) as previously described, on the left sciatic
nerve (Decosterd and Woolf, 2000). In sham animals, the nerves
were bared but left untouched.
SURFACE BIOTINYLATION
Conﬂuent cells from 75 cm2 ﬂasks were incubated for 30 min at
4◦C with Biotin-solution (0.3 mg/ml in PBS, Thermo Scientiﬁc,
Germany) and then washed twice in PBS. Cell were solubilized
1 h at 4◦C, on agitation in lysis buffer (Hepes 50 mM pH 7.4,
NaCl 150 mM, MgCl2 1.5 mM, EDTA 1 mM, glycerol 10%, Triton
X-100 1% and N-ethylmaleimide 1.2 mg/ml) supplemented with
antiproteases. Homogenates were centrifuged (12,000 g, 15 min)
and proteins were quantiﬁed in the supernatant using the Brad-
ford method. 500 μg of proteins were incubated with 50 μl of
streptavidin/Neutravidin-sepharose beads (GE Healthcare, USA)
on agitation at 4◦C and samples were centrifuged (1000 g, 2 min).
S1 supernatants (corresponding to the non-biotinylated fractions)
were supplemented with 5× sample buffer and stored at −20◦C
until use. Pellets were washed 5 times with lysis buffer supple-
mented with antiproteases and after the ﬁnal wash, 2× sample
buffer was added before incubation at 90◦C for 5 min. Samples
were centrifuged (3000 g, 5min) and S2 supernatants (biotinylated
fractions) were stored at −20◦C until use. S1 and S2 fractions were
processed for western-blot analysis.
SUBCELLULAR FRACTIONATION
Cellsweremechanically resuspended in ice-cold 0.8Msucrose/Tris
10 mM/pH 7.4 (300 μl, fractionation buffer) and submitted to 10
strokes through a 26 gauge needle. For in vivo experiments, per-
formed at 7 days post-surgery, spinal dorsal halves were isolated,
homogenized (motor pestle) in fractionation buffer (300 μl) and
centrifuged at 1000 g for 10 min. Cell homogenates or spinal
post-nuclear supernatants were loaded on top of a linear sucrose
gradient (15–50%, in Tris 10 mM, pH 7.4, 3.2 ml in total) and
centrifuged at 100,000 g for 2 h. Fourteen fractions (250 μl) were
collected from bottom (high density) to top (low density) and
stored at −80◦C until use. For quantiﬁcation of subcellular frac-
tionation, the signal in each fraction was expressed as a ratio over
total signal. All comparisons were made between samples that
had been collected from the same series of cultures and ultra-
centrifuged together, to minimize the slight variations between
different subcellular fractionations.
ISOLATION OF MICROVESICLES
Microvesicles were isolated as previously described, with minor
modiﬁcations (Caby et al., 2005; Alvarez-Erviti et al., 2011).
Brieﬂy, conditioned media from cells or spinal explants were cen-
trifuged at 1500 g for 5 min and at 3000 g for 10 min to remove
non-adherent cells, cell debris and apoptotic blebs. Supernatants
were then ultracentrifuged at 100,000 g for 2 h and the microvesic-
ular pellets were resuspended in western-blot loading buffer or
phosphate buffer saline (PBS).
NANOPARTICLE TRACKING ANALYSIS
Nanoparticle tracking analysis was performed using theNanosight
LM10-HS system (NanoSight, Amesbury, UK) as previously
described with minor modiﬁcations (Soo et al., 2012). Brieﬂy,
eMV from astrocytes were prepared as described above and resus-
pended in PBS (1 ml of PBS for eMV corresponding to the
conditioned medium from 75 cm2 of conﬂuent astrocytes). Fifty
microliters of the suspension were diluted 10 times in PBS for
analysis (ﬁnal volume 500 μl) and injected into the chamber of the
apparatus. The technique employs a laser beam passing through
the suspension of particles that are visualized by light scattering
using a standard optical microscope. The Brownian motion of
each particle is tracked between frames, and the Nanosight soft-
ware calculates the size of each particle that passes in the ﬁeld using
the Stokes–Einstein equation.
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[3H] ASPARTATE REUPTAKE
Reuptake experiments on cultured astrocytes were conducted as
follows. Cell medium was changed and astrocytes were ﬁrst equi-
librated for 5 min with incubation buffer (KCl 5.33 mM; NaHCO3
26.2 mM; NaCl 117.2 mM; NaH2PO4 1 mM; CaCl2 1.2 mM;
HEPES 1 mM; D-Glucose 5.6 mM; pH 7.4). Radiolabelled aspar-
tate (50 nM ﬁnal, 23.9 Ci/mmol, Amersham, Buckinghamshire,
UK) was added and left to incubate for 5 min at RT. Cells were
then washed three times with ice-cold incubation buffer to stop
aspartate transport and lysed with 1 N NaOH + 0.05% sodium
dodecyl sulfate in water. Radioactivity was estimated by liquid
scintillation.
For [3H] aspartate reuptake on eMV, astrocyte medium was
centrifuged for 5 min at 1500 g and 10 min at 3000 g before being
supplemented with 20% incubation medium. Three samples were
then incubated for 5 min with (2S,3S)-3-[3-[4-(triﬂuoromethyl)-
benzoylamino]-benzyloxy]aspartate (TFB-TBOA, 100 nM ﬁnal,
generous gift from Dr. Jean-Yves Chatton; Bozzo and Chatton,
2010) and 3 samples were left untouched. [3H] aspartate (50 nM
ﬁnal) was added and left to incubate for 5 min at RT before media
were ultracentrifuged 2 h at 100.000 g. The microvesicular pellet
was then lysed in 1 N NaOH + 0.05% sodium dodecyl sulfate and
the radioactivity counted by liquid scintillation.
WESTERN-BLOT
Western-blot was done as previously described (Gosselin et al.,
2010a). The following antibodies were used (over-night, 4◦C):
rabbit anti-EAAT-1, EAAT-2, GAT-1 and GAT-3 (1/5000; Abcam,
USA), caveolin-1 (1/200; Santa Cruz, USA), NaK ATPase β sub-
unit (1/1000; generous gift from prof. Kaethi Geering), Iba-1
(1/1000; Wako, Japan), EEA1 (1/500; Cell Signaling, USA),
mouse anti-glial ﬁbrilary acidic protein (GFAP, 1/2000; Millipore,
USA), NaK ATPase α subunit (1/1000; Abcam, USA), glutamine
synthetase (1/5000; generous gift from Prof. Andrea Volterra),
α-tubulin (1/10000; Sigma, USA) and Alix (1/2000; Abcam,
USA). For phospho-PKC, rabbit monoclonal antibodies were used
(1/1000; sampler kit, Cell Signaling, USA). For quantiﬁcation, we
used ImageJ freeware; quantiﬁcation was made using Coomassie
normalization for loading control.
IMMUNOFLUORESCENCE
Immunoﬂuorescence was performed as previously described
(Gosselin et al., 2010a) on cryostat-cut 18 μm thick spinal sections
from paraformaldehyde (PFA)-perfused rats or on PFA-ﬁxed cells
grown on coverslips. The following antibodies were used: rab-
bit anti-EAAT-1 (1/500; Abcam, USA), EAAT-2 (1/50; Abcam,
USA), phospho-PKC (all antibodies 1/100), s100β (1/500; Sigma,
USA), PGP9.5 (1/1000; Accurate Chemicals, USA), mouse anti-
NeuN (1/300; Millipore,USA), glial ﬁbrilary acidic protein (GFAP;
1/1000; Millipore, USA), glutamine synthetase (1/500; generous
gift from Andrea Volterra). Nuclei were visualized by DAPI stain-
ing (5 min) in the ﬁrst washing bath after secondary antibody.
Digital imageswere all processedwith the same settings to improve
the contrastswith noparticular part of any picturesmodiﬁed inde-
pendently. For evaluation of PMA toxicity, 6 ﬁelds per well from
3 wells of 24-well microplates (40× magniﬁcation) were used per
condition using DAPI labeling.
SPINAL EXPLANTS
Under terminal pentobarbital anesthesia, rats were exsanguinated
by decapitation and L4–L5 spinal cords were quickly isolated
by laminectomy and collected in DMEM/glutamax (Invitrogen,
USA), 10% normal calf serum with pennicillin/streptomycin
(Invitrogen, USA). Tissues (approximately 5 mm in length) were
then cut into 400 μm thick slices using a McIlwain tissue chop-
per (Mickle laboratories, UK). Explants were singly transferred in
500 μl of medium in 24-well microplates and incubated 24 h in
a humidiﬁed 95% CO2 incubator at 37◦C. Conditioned medium
was pooled for each animal and processed for eMV isolation.
STATISTICAL ANALYSIS
All statistics were performed using GraphPadPrism software (ver-
sion5.01,GraphPad,USA); all data are expressed asmean±S.E.M.
For reuptake analysis, western-blot analysis of EAAT-1 in eMV
and survival assay on cultured cells, one-way ANOVA was used,
followed by Dunnett’s post hoc test vs. vehicle. For subcellular
fractionation from cultured cells, two-ways ANOVA was used,
followed by Bonferroni’s post hoc test. For reuptake on isolated
eMV and for western-blot analysis of eMV from spinal explants,
unpaired two-tailed Student’s t-test with Welch correction for
unequal variances was used. For all other western-blot explo-
rations, unpaired two-tailed Student’s t-test was used. For all
statistics, threshold was set up at p < 0.05.
RESULTS
PKC ACTIVATION MODIFIES SUBCELLULAR DISTRIBUTION OF EAAT-1
Primary cultures of astrocytes fromnewborn ratswereused to clar-
ify the regulation of EAATs by PKCs. Quantiﬁcation of cellmarkers
in our culture by immunoﬂuorescence gave the following propor-
tions in astrocyte cultures: GFAP positive cells 45.8 ± 2.1% of total
nuclei (72/160 nuclei in 5 ﬁelds, from a single culture); glutamine
synthetase positive cells 74.5± 0.9%of total nuclei (135/183 nuclei
in 5 ﬁelds); Iba1 positive cells 2.4 ± 0.8% of total nuclei (5/188
nuclei in 5 ﬁelds). In cultured astrocytes, western-blot analy-
sis revealed EAAT-1 expression, as opposed to EAAT-2, GABA
transporters (GAT)-1 and GAT-3, although all transporters were
detected in spinal cord and brain samples (Figure 1A). We there-
fore focused our in vitro investigations on EAAT-1. Treatmentwith
PMA elicited PKC activation as well as downstream ERK1/2 phos-
phorylation (Figure 1B). Confocal immunoﬂuorescence revealed
a profound reorganization of EAAT-1 immunoreactivity upon
PMA exposure from a widespread signal throughout the cell to
a highly condensed perinuclear cytosolic localization (Figure 2A).
This PMA-triggered reorganization of EAAT-1 immunoreactiv-
ity was abolished by pretreatment with pan-PKC inhibitor CHE.
Surface biotinylation shows that PMA treatment reduces the ratio
between surface (S2) and intracellular (S1) EAAT-1 conﬁrming the
PKC-driven EAAT-1 internalization (Figure 2B). We further used
ultracentrifugation on sucrose gradient (subcellular fractionation)
to explore EAAT-1 subcellular distribution (Figures 2C,D). This
technique allows the separation of cellular organelles according
to their densities. The distribution pattern of EAAT-1 indicated a
bimodal enrichment in fractions 1 to 2 and 7 to 11. Upon PMA
treatment, a full leftward shift was observed for EAAT-1 signal,
toward low-density with low protein level remaining in fractions
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 251 | 3
“fncel-07-00251” — 2013/12/7 — 12:30 — page 4 — #4
Gosselin et al. Extracellular glial glutamate transporters
FIGURE 1 | Primary astrocytes express EAAT-1 and respond to PMA.
(A)Western-blots showing that EAAT-1 is detected in cultured astrocytes,
as opposed to EAAT-2 or GABA transporters GAT-1 and GAT-3. Coomassie
stain (coom) is shown in the lower panels as a loading control (similar
images reﬂect multiple incubations of the same membranes with different
antibodies). Signals obtained from dorsal spinal cord and brain are also
shown as positive controls. Molecular weights (kDa) are given on the right.
(B)Western-blot verifying the capacity of PMA (1 μM, 10 min) to activate
the PKC pathway (pan-phospho PKC, upper panel) and downstream
cascades (phospho ERK).
3 to 13. A shift toward low-density fractions was also observed for
caveolin-1. Pretreatment with panPKC inhibitor CHE preserved
EAAT-1 in fractions enriched in plasma membrane (signiﬁcantly
in fractions 9 and 10) and preserved low EAAT-1 in fractions 1–2.
CHEpretreatment had only amild effect on PMA-driven caveolin-
1 readdressing, with a partial signal restoration in fractions 9–13
but without a full disappearance of caveolin-1 from fractions of
lower density (Figure 2C). Analysis of organelle markers shows
that fractions enriched in plasma membrane markers (sodium
potassium pump, NaK ATPase: fractions 3 to 13; caveolin-1: frac-
tions 5 to 7 and 10 to 13) were distinct from fractions containing
markers for endomembranes (early endosomes, EEA-1: fraction
1; late endosomes, Alix: fractions 1 and 2). This distribution pat-
tern suggests that in basal conditions EAAT-1 is distributed at
both plasmalemmal and endomembrane sites and that upon PKC
activation it is routed toward the endosomal compartment. Func-
tionally, exposure to PMA was effective at signiﬁcantly reducing
[3H]-Aspartate reuptake from cultured astrocytes (Figure 2E). To
explore the possibility that the observedPMA-drivenEAAT-1 plas-
ticity might be linked to a non-speciﬁc toxic effect, we examined
whether cell death was provoked by PKC activation. No increase
in the percentage of apoptotic nuclei could be found by morpho-
logical analysis of nuclear DAPI labeling 24 h (1.2 ± 1.0%) or
48 h (1.9 ± 0.8%) post-PMA as compared to vehicle-treated cells
(1.6 ± 0.5%). Similarly, 24 h or 48 h PMA exposure did not reduce
the total number of counted nuclei per ﬁeld when compared to
vehicle treatment (25.5 ± 1.5, 24.9 ± 1.4, 26.4 ± 1.3, respectively).
CONSTITUTIVE AND PKC-SENSITIVE EAAT-1 ENRICHMENT IN
ASTROCYTIC MICROVESICLES
We investigated whether PKC activation could trigger the release
of the transporter into eMVs. Conditioned cell culture media
were ultracentrifuged and eMV-enriched pellets were analyzed
(Figure 3). Figure 3A shows that both conditioned medium from
astrocytes and microglia, as well as culture medium with serum,
contained eMV as assessed by the detectable signal for membrane
α subunit of NaK ATPase. xxx No signal for the β subunit of NaK
ATPase could be found in eMV from cultured cells (not shown).
EAAT-1 could only be detected in eMV isolated from astrocytic
medium (Figure 3A), together with a weak but visible signal
for glutamine synthetase. EAAT-1 expression could be detected
in protein extracts from microglia as well, but not in microglia-
derived eMV (Figures 3A,B). A reuptake experiment shows that
a signiﬁcant amount of [3H] aspartate can be incorporated in
eMV and that this transport is sensitive to the selective EAAT
blocker TFB-TBOA (Figure 3C), indicative of a functionality of
eMV transporters.
Treatments of astrocytes with PMA for 9 h with no change
of culture medium strongly increased the detectable signal for
EAAT-1 (Figure 3D). Similarly, we found an increased signal for
α-NaK ATPase and glutamine synthetase with no modiﬁcation of
Coomassie staining suggesting that protein targeting to the vesi-
cles was modiﬁed with no change in the overall eMV release. De
novo protein enrichment induced in eMV by PKC activation was
assed by a full replacement of culture medium just prior treatment
with PMA, followed by microvesicle isolations after 30 min or 6 h.
This approach allows assessing the protein turnover in newly syn-
thetized vesicles rather than a change in already released eMV. This
procedure has induced an increase of EAAT-1 signal in eMV,which
reached statistical signiﬁcance only in samples treated 6 h prior to
eMV collection (Figure 3E).
We investigated which of the different isoforms of PKC could
be responsible for the regulation of EAAT-1 following PMA appli-
cation. Marked phosporylations of PKC-δ and -θ were detected in
response to PMA, with no effect on α/β or ε isoforms (Figure 3F).
Pretreatment of astrocytes with rottlerin counteracted the signif-
icant increase of EAAT-1 in eMV induced by PMA (Figure 3G).
The concentration of rottlerin that we employed is within the
range of concentration allowing a selective inhibition of the PKC-
δ isoenzyme with an IC50 of 3–6 μM against PKC-δ, as opposed to
30–100 μM for α, β, γ, ε, and ζ isoforms (Gschwendt et al., 1994).
PCK-ζ was monitored to assess the speciﬁcity of activation, as the
activation of this atypical isoform is insensitive to PMA.
We further explored the structural properties of astrocytic
eMV using laser-based nanoparticle tracking analysis (Figure 4).
6 h after PKC activation, we found no signiﬁcant alteration
of mean particle diameter (139.0 ± 3.1 vs. 135.4 ± 2.5 nm),
median particle diameter (96.0 ± 2.7 vs. 94.0 ± 5.2 nm) or
particle concentration (22.6 ± 1.2 vs. 25.2 ± 1.6 × 108 parti-
cles ml−1) in conditionned medium (Figure 4A; p = 0.4048,
0.7408, 0.2237, respectively; Student’s t-test). In addition, we
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FIGURE 2 | PKC activation modifies EAAT-1 sub-cellular distribution in
primary astrocytes. (A) Fluorescence confocal microscopy showing the
EAAT-1 immunoreactivity in vehicle-treated (left picture), PMA-treated
(middle panel) and PKC inhibitor chelerythrine (CHE)/PMA-treated astrocytes
(right picture). Scale bar: 10 μm. (B) Surface biotinylation of astrocytes
showing the increased signal for internalized EAAT-1 (S1, non-biotinylated)
and reduced surface EAAT-1 (S2, biotinylated) after PMA. One lane
represents a homogenate from 75 cm2 conﬂuent astrocytes.
Quantiﬁcations were made from 5 blots corresponding to 5 independent
ﬂasks. **p < 0.01, Student’s t -test. (C) Subcellular fractionation by
ultracentrifugation on sucrose gradient followed by western-blot showing
that PMA treatment produces a relative enrichment of EAAT-1 in low
density fractions 1–2 also rich in early (EEA1) and late (Alix) endosomes, as
opposed to the reduction of EAAT-1 signal in plasma membrane (NaK
ATPase) rich fractions 7–11. Pretreatment with CHE fully abolishes the
EAAT-1 enrichment in fractions 1–2 both constitutively or upon PMA. (D)
Bar histogram showing the quantiﬁcation of EAAT-1 subcellular fractionation
as a percentage of total signal. *p < 0.05; **p < 0.01; ***p < 0.001, two
ways ANOVA, followed by Bonferroni post hoc test (n = 3 independent
blots from 3 independent cultures). (E) [3H] Aspartate reuptake showing
the inhibitory effect of PMA on the transport capacity of astrocytes (black
bars) as compared to vehicle-treated cells (VH, white bar). ***p < 0.001
one way ANOVA followed by Dunnet’s post hoc test vs. vehicle column
(n = 6 wells per condition).
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FIGURE 3 | Extracellular microvesicles from astrocytes contain
functional EAAT-1. (A) Representative western blots showing NaK ATPase,
EAAT-1 and glutamine synthetase in astrocyte-derived eMV, whereas only
NaK ATPase is detected in eMV from microglia or serum. Lanes correspond
to medium from 75 cm2 of conﬂuent cells. Coomassie staining (coom) shows
total protein content. (B)Western blots of astrocyte (GFAP positive) and
microglia (Iba-1 positive) extracts showing that both cell types express EAAT-1
in culture (10 μg of proteins extracts loaded). (C) Bar graph showing [3H]
aspartate reuptake from astrocyte-conditioned medium treated (black bar) or
not (white bar) with the speciﬁc EAAT blocker TF-TBOA. Given as
mean ± SEM. **p < 0.001, t -test withWelch correction, n = 3 samples from
3 independent dishes. (D)Time course study of eMV composition in
response to PMA without medium replacement. An enrichment of NaK
ATPase and glutamine synthetase is found at 6 and 9 h post-treatment
together with an increase of EAAT-1 signal after 9 h, but without
modiﬁcations of Coomassie staining. Bar graph shows quantiﬁcation of
EAAT-1. **p < 0.01, one way ANOVA followed by Dunnett’s post hoc test vs.
control column (n = 4 samples from independent cultures for each condition).
(E)Time course study (30 min and 6 h) of microvesicular NaK ATPase and
EAAT-1 in response to PMA after a full medium change. A signiﬁcant
augmentation of EAAT-1 is observed 6 h post-PMA in comparison to eMV
from vehicle treated cells.*p < 0.05, one way ANOVA followed by Dunnett’s
post hoc test vs. control column (n = 4 samples from independent cultures).
(F)Western-blots showing the PKC isoforms activated in primary astrocytes
after PMA treatment. PMA treatment increases phospho-PKC-δ and -θ.
Coomassie staining (coom) shows the total protein content. (G)Western blot
showing that rottlerin counteracts the increase of EAAT-1 in eMV after PMA.
The bar histogram shows the quantiﬁcation of band intensities. *p < 0.05,
one way ANOVA followed by Dunnett’s post hoc test vs. control column
(n = 3 independent cultures for each condition).
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FIGURE 4 | Protein kinase C activation in primary astrocytes does not
result in changes in eMV size or concentration. (A) Bar graph showing
the quantiﬁcations of mean diameter (left panel), median diameter (middle
panel) and eMV concentration (right panel) in astrocytes conditioned
medium 6 h after vehicle (white bars) or PMA (black bars) exposure. No
signiﬁcant difference could be found (Student’s t -test, n = 5 separate
conﬂuent ﬂasks). (B) Size proﬁle of eMV from vehicle (white circles) or
PMA (black circles) treated astrocytes (n = 5 separate conﬂuent ﬂasks for
each condition).
wanted to evaluate whether PKC activation generates subsidiary
populations of vesicles that would not have signiﬁcantly affected
the global mean or median eMV diameter. Detailed analy-
sis indicates that PMA exposure did not result in the emer-
gence of secondary eMV populations with divergent diameter
(Figure 4B). It is worth mentioning, however, that our iso-
lation procedure might not be sensitive enough to distinguish
biochemically divergent subpopulations of eMV with overlapping
diameters.
SPINAL ASTROGLIOSIS IS ASSOCIATED WITH PKC-δ ACTIVATION AND
EAAT-1 REORGANIZATION
We next determined whether PKC activation occurs in vivo dur-
ing central astrogliosis induced by peripheral nerve injury. We
used the SNI model of the sciatic nerve, which is well described
for generating an astrocytic reaction in the ipsilateral spinal cord
(Vega-Avelaira et al., 2007; Cirillo et al., 2011). After SNI, western-
blots showed ipsilateral increases of phospho-PKC-δ (p = 0.0005),
θ (p= 0.0023) and ζ (p= 0.0084)with no signiﬁcant change inα/β
or ε (Figure 5). Double labeling immunoﬂuorescence (Figure 6B)
showed that phospho-PKC-δ colocalizes with astrocytic markers
FIGURE 5 | Peripheral nerve injury induces the activation of PKC-δ, -θ
and -ζ in the spinal cord. (A)Western blots showing phosphorylated PKC
isoforms in the ipsilateral dorsal spinal cord of SNI and sham. (B) Bar
graphs indicating the optical quantiﬁcation of band intensity, as a ratio over
Coomassie staining and normalized over sham, expressed as mean ± SEM.
n.s., non signiﬁcant; **p < 0.01; ***p < 0.001 t -test, sham vs. SNI, n = 6
for each condition. A signiﬁcant activation of PKC-δ, -θ and -ζ is found.
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FIGURE 6 | Following peripheral nerve injury, astrocytes are the source
of PKC-δ activation. (A) Schematic showing the region of interest in the
spinal dorsal horn. (B) Immunoﬂuorescence highlighting spinal GFAP
immunoreactivity one week after sham (left picture) or in SNI surgery (right
picture). Scale bar 100 μm. (B,C) Immunoﬂuorescence detecting isoforms
of phospho PKC. (C) A colocalization is found between markers for
astrocytes (s100β, GFAP and glutamine synthetase, red) and activated
PKC-δ and -ζ (green, ﬁrst and third columns). No overlap was found
between phospho PKC θ and astrocytes. (D) Phospho-PKC-θ and -ζ, but
not phospho-PKC-δ colocalizewith neuronal marker (NeuN, upper images).
No isoform could be detected in microglia (CD11b, lower images). Scale
bar, 100 μm.
S100β, GFAP and glutamine synthetase. Noteworthy, phospho-
PKC-δ was found particularly in perivascular astrocytes. No
colocalization was found between phospho-PKC-δ and neuronal
markers NeuN or microglial protein CD11b (Figure 6C). Con-
versely, phospho-PKC θ colocalized with NeuN. Phospho-PKC-ζ
was found mostly in subsets of neurons (Figure 6C) but also in
scattered astrocytes (Figure 6B). None of these phospho-PKC
isoforms was found to overlap with microglial marker CD11b
(Figure 6C).
We therefore investigated whether EAAT-1 undergoes subcel-
lular reorganization in the dorsal horn of the spinal cord after SNI
(Figure 7). Astrogliosis resulted in modiﬁcations of EAAT-1 and
EAAT-2 detected in subcellular fractionation, with a signiﬁcant
shift toward fractions of lower densities, containing caveolin-1.
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FIGURE 7 | (A–D) subcellular fractionation presented as bar histograms,
showing the distribution patterns of glutamate and GABA transporters as a
percentage over total signal in all fractions. A leftward shift is observed for
EAAT-1 (A) and EAAT-2 (B). *p < 0.05; **p < 0.01, sham vs. SNI, t -test with
Bonferroni correction for multiple comparisons (n = 5–6 rats for each
condition). Arrows in (A) indicate signal detected in SNI samples with no
counterparts in sham fractions. (E) Representative immunoblots of
subcellular fractionation illustrating the shift of EAAT-1 and EAAT-2 content in
SNI spinal cord, in the caveolin-1 enriched fractions. Arrowheads indicate
fractions that are sites or EAAT-1 increase in SNI animals.
A signiﬁcant increase in EAAT-1 signal was detected in frac-
tion 8 (p = 0.0454), the protein became detectable in fractions
3 to 6, and a reduction of EAAT-1 content was found in frac-
tion 10 (p = 0.0025; Figures 7A,E). A signiﬁcant intensiﬁcation
of EAAT-2 occurred in fraction 5 (p = 0.0029) in SNI samples
(Figure 7B). Remarkably, no EAAT modiﬁcations could be found
in fractions 1 and 2, enriched in endosomal EEA1. There was
no change on either side for NaK ATPase, GAT-1 or GAT-3 nor
for EAAT contralaterally to SNI (Figures 7A–E), suggesting the
speciﬁcity of ipsilateral EAAT subcellular plasticity following SNI.
The amplitude of this shift is nevertheless much smaller than the
modiﬁcation obtained in primary astrocytes after PMA treatment
(Figure 1E). We quantiﬁed EAAT-1 and EAAT-2 using western-
blot of total extracts from ipsilateral spinal dorsal halves from
sham and SNI rats (not shown). We found no statistical differ-
ence of EAAT-1 signal between the two groups of rats, whereas
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FIGURE 8 | EAAT-1 immunofluorescence is exclusively astrocytic. (A)
colocalization (yellow, right panel) between: EAAT-1 (green) and astrocytic
s100β (red); (B) No colocalization between EAAT-1 (green) and neuronal
NeuN (red). (C,D) EAAT-2 (green) is found in both astrocytes and some
scattered neurons. Inserts show higher magniﬁcations. Scale bar,
100 μm.
EAAT-2 was signiﬁcantly increased in SNI animals (p = 0.5994
and 0.0127 for EAAT-1 and EAAT-2 respectively, t-test, n = 7
animals in each group). Finally, immunoﬂuorescence showed a
strong coincidence between EAAT-1 and the astrocytic protein
s100β, but not with neuronal marker NeuN (Figure 8), supporting
the astrocytic source of EAAT-1. Conversely, EAAT-2 immunore-
activity was found in subsets of both s100β and NeuN expressing
cells, thus conﬁrming the mixed source of EAAT-2 (de Vivo et al.,
2010).
SPINAL ASTROCYTIC ACTIVATION INCREASES THE eMV RELEASE OF
EAAT-1 AND EAAT-2
The PKC activation and EAAT-1 subcellular reorganization gen-
erated during spinal astrogliosis suggest that an enrichment of
EAAT in eMV might occur in parallel. We therefore charac-
terized the eMV released by spinal explants from sham or SNI
rats. In conditioned medium from spinal explants from sham
animals, both α and β subunits of NaK ATPase were detected
as well as glutamine synthetase, Alix, α tubulin and EAAT-2 as
opposed to very low levels of EAAT-1 (Figure 9A). In condi-
tioned media released by explants from neuropathic animals, a
signiﬁcant increase of α/β NaK ATPase (p = 0.0005 and 0.0012,
respectively), EAAT-1 (p = 0.0285) and EAAT-2 (p = 0.0217) were
found (Figure 9B). No change of glutamine synthetase, Alix or α
tubulin contents could be detected (p = 0.1715,). In addition, we
found no apparent modiﬁcation of total protein content between
samples from sham or SNI explants, quantiﬁed by Coomassie
staining. Nonetheless, it has been shown (Verderio et al., 2012)
that eMV derived from all neural cells can be detected for instance
in the cerebrospinal ﬂuid. We therefore cannot fully exclude that
the observed changes stem from eMV released by non-astrocytic
cells.
DISCUSSION
Our major result is that in astrocytes the enrichment of EAAT-1 in
eMV is under the control of PKC. The activation of PKCs results in
a reduction of the astrocytic glutamate transport, associated with a
profound modiﬁcation of EAAT-1 subcellular distribution toward
both an intracellular pool and secreted microvesicles. Addition-
ally, we suggest that the increased EAAT in eMV following PKC
activation is a consequence of a selective routing of transporters to
the microvesicular compartment rather than an increased number
of secreted eMV. Moreover, glutamate transporters in astrocytic
eMV are functional and we show that astrocytic reaction results in
both a subcellular reorganization of EAAT and an increased EAAT
content in released eMV (Figure 10).
The biochemical signals driving the enrichment of a cargo
protein to eMV are a subject of current investigation but the
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FIGURE 9 | Spared nerve injury spinal explants are enriched in EAAT-1
and EAAT-2. (A)Western blots illustrating the increased NaK ATPase,
EAAT-1, EAAT-2 but not glutamine synthetase, Alix, α tubulin or total protein
content (Coomassie) contents in eMV from SNI rats as compared to
counterparts from sham animals. (B) Quantiﬁcation of western blot signals
conﬁrming the statistical increases observed in (A). Given as mean ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001; n.s., non signiﬁcant. Student’s t -test
withWelch correction for unequal variances, sham vs. SNI (n = 3 explants
from different animals per condition).
available data remain scant (Bobrie et al., 2011; Hurley and Odor-
izzi, 2012). Nevertheless, the control exerted by PKCs on the
circulation of EAAT-1 between the plasma membrane and intra-
cellular pools has been demonstrated (Susarla et al., 2004; Sheldon
et al., 2008; Susarla and Robinson, 2008). Our present study is, to
our knowledge, the ﬁrst to demonstrate that PKCs also govern
the routing of EAAT-1 to eMV. Little is known about the sig-
naling pathways regulating the release of eMV. One important
identiﬁed pathway is the cascade involving sphingomyelinases and
leading to the production of ceramides (Trajkovic et al., 2008;
Yuyama et al., 2012), especially in astrocytes (Wang et al., 2012).
Interestingly the PKC family, and particularly PKC-δ, has been
identiﬁed as an important activator of sphingomyelinases and
ceramide generation (Zeidan and Hannun, 2007; Clarke et al.,
2008), which prompts further complementary exploration of a
possible involvement of this pathway in EAAT sorting in astro-
cytic eMV. Besides, our results suggest that PKC drives subcellular
reorganization of EAAT-1 and caveolin-1 in comparable frac-
tions. This putatively points to a co-segregation of EAAT-1 into
caveolae, a caveolin-rich form of lipid rafts (Lajoie and Nabi,
2010), in which EAAT have been previously detected (Escartin
et al., 2006). The functional consequences of the connection
between EAAT-1 and caveolin-1 are unclear. Nevertheless, numer-
ous convergent studies establish both that eMV (exosomes and
shedding microvesicles) contain rafts components and that eMV
may arise from caveolae or lipid rafts (de Gassart et al., 2003;
Del Conde et al., 2005; Chen et al., 2011; Valapala and Vish-
wanatha, 2011). It is however worth mentioning that CHE has
dissimilar effects on PMA-induced re-addressing of EAAT-1 and
caveolin-1, suggesting that the control exerted by PKC on EAAT-
1 sorting extends beyond the sole incorporation in caveolae. It
is worth pointing that our objective was to detect and quantify
eMV release from astrocytes, and that the full description of eMV
heterogeneity is not assessed in our experiments. Future studies
using more reﬁned isolation protocols may add new informa-
tion about different populations of eMV, especially whether the
released vesicles comprise exosomes or shedding microvesicles.
This investigation was however, beyond the scope of our present
study.
Our cultured neonatal astrocytes express EAAT-1 and not
EAAT-2, thus all our present in vitro explorations were oriented
toward the description of EAAT-1 regulation upon PKC activa-
tion. Nevertheless, the detection of EAAT-2 in eMV secreted by
spinal explants after nerve injury suggests that mature astrocytes
in their native cytoarchitectural environment address EAAT-2
to eMV as well. Remarkably, the previously described regula-
tion of EAAT-2 subcellular sorting by PKC pleads in favor of
a similar PKC-driven control of EAAT-2 addressing to eMV
(Kalandadze et al., 2002; Sheldon et al., 2008; Susarla and Robin-
son, 2008). We found that the spinal astrocytic reaction gen-
erated after peripheral nerve injury was associated with: (i)
the phosphorylation of PKC-δ and θ; (ii) a shift of gluta-
mate transporters EAAT-1 and EAAT-2 from fractions with high
contents of NaK-ATPase toward intermediate densities, with
enrichment in caveolin-1; (iii) and an increased EAAT-content
in eMV. No change was observed for GABA transporters GAT-
1 and GAT-3 suggesting that EAAT reorganization is selective.
Remarkably, the magnitude of EAAT-1 subcellular reorganiza-
tion in vivo is lower than in PMA-treated astrocytes, suggesting
that a limited number of astrocytes undergo such plasticity
in SNI. Additionally, this phenomenon might be limited in
vivo to a restricted percentage of EAAT-1 proteins within the
cells.
Excitatory amino-acid transporters uses the electrochemical
plasmalemmal gradient of Na+, generated by the NaK ATPase,
to transport glutamate that will subsequently be converted into
glutamine by glutamine synthetase. EAAT and NaK ATPase
even physically assembly into a multi-protein complex, thus
promoting functional coupling between glutamate transport and
plasmalemmal ion ﬂux (Rose et al., 2009). Therefore, the detection
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FIGURE 10 | Schema highlighting the trafficking of glutamate
transporters in resting or reactive astrocytes. In homeostatic conditions
(upper panel), both EAAT-1 and -2 are enriched at the plasma membrane
providing an efﬁcient glutamate reuptake (A; see Figures 2 and 7) as well
as in intracellular early (B) or late (C) endosomal pools (Figure 2).
Furthermore, EAAT are also constitutively targeted to eMV (D; see
Figure 3) together with glutamine synthetase and NaK ATPase, especially
EAAT-2 in vivo (see Figure 9). During astrocytic reaction associated with
pathological conditions (lower panel; see Figure 6) the activation of PKC
(E; see Figure 2) and in particular PKC-δ (see Figures 3,5, and 6) drives
the internalization of EAAT to the endosomal compartment (F; see
Figures 2 and 7). The result is an apparent loss of astrocytic reuptake
capacity (see Figure 2). This PKC-driven EAAT internalization ultimately
leads to increased transporter packing (G) and secretion in eMV (H)
together with glutamine synthetase and NaK ATPase (Figures 3 and 9).
However, no overall increase of eMV release is generated (Figures 3,4,
and 9). The ability of eMV to reuptake glutamate (see Figure 3) together
with the concomitant presence of glutamine synthetase and NaK ATPase
(see Figure 9) might bestow an increased extracellular capacity to convert
glutamate to glutamine.
of this full protein arsenal in eMV from astrocytes suggests that
microvesicular EAAT might have a functional extracellular role in
glutamate elimination. Notably, we did not detect the regulatory
β subunit of NaK ATPase in astrocyte-derived eMV, suggest-
ing that another subunit might act as a surrogate interacting
partner for α NaK ATPase as previously described (Horisberger
et al., 1991). In accordance with the theory of an eMV-based
glutamate detoxiﬁation, we found that eMV have the capacity to
reuptake [3H] aspartate, indicating that microvesicular EAAT are
functional. This could constitute an important conceptual break-
through, as eMVs are widely considered important in intercellular
communication, but practically unexplored for possible extracel-
lular roles (Mathivanan et al., 2010). In support of this hypothesis,
the careful exploration of the Exocarta compendium reveals that
beyond EAAT, a wide range of membrane transporters has been
detected in eMV from multiple origins. These include trans-
porters for glucose, nucleosides, urate, peptides or amino acids
mostly belonging to the solute carrier family (SLC), which also
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encompass EAAT. Strikingly, other transporters for neurotrans-
mitters are found in this list, such as serotonin andγ amino-butyric
acid (GABA) transporters, suggesting that extracellular reuptake
functions of eMV might extend beyond glutamate.
The increase of EAAT and NaK ATPase in eMV during
neuroinﬂammatory astrogliosis might therefore have functional
consequences through an enhancement of the buffering capacity
for extracellular glutamate. This could constitute a compensatory
mechanism in response to increased glutamate release and more
broadly as a consequence of a rise in glutamatergic transmission,
as encountered following peripheral nerve injury (Larsson, 2009;
Larsson and Broman, 2011). Further in-depth investigations are
required to establish whether NaK ATPase, EAAT and glutamine
synthetase coexist in the same microvesicles or are simultane-
ously released in different pools of eMV. In particular, as we also
found EAAT-2 immunoreactivity in neuronal cells, it is possi-
ble that this transporter is partly released through a neuronal
pool of eMV. Nevertheless, one cannot rule out the possibility
that EAAT-containing eMV may play a role in intercellular com-
munication in addition to extracellular glutamate buffering. The
question therefore arises of the biological signiﬁcance of a trans-
cellular transfer of glutamate transporters. One may hypothesize
that astrocytes synthetizing high amounts of EAAT initiate an
eMV-mediated transfer of these proteins to cells expressing low
rates of transporters, thus allowing a harmonization of parenchy-
mal reuptake. Alternatively, reactive astrocytes might reduce their
ability to scavenge synaptic glutamate through the reorientation
of EAAT from the plasma membrane surrounding the synaptic
cleft toward secreted eMV and a further extracellular pool des-
tined to trans-cellular degradation. The short time-scale (minutes)
of such regulation might constitute an advantage over transcrip-
tional regulations that may necessitate hours to functionally echo
on glutamate transport.
Peripheral nerve lesions, in particular the SNI model used
in this work, are often used as models of chronic neuropathic
pain (Decosterd and Woolf, 2000). These models are associated
with a well-described astrocytic reaction in the spinal cord that is
important in the perpetuation of sensory deregulations, in par-
ticular those due to alterations of EAAT (Gosselin et al., 2010b).
However, astrocytic reactions take place in a wide variety of neu-
rological conditions indicating that the deregulation of astrocytic
eMV might have far-reaching consequences in neuropathology.
Neuroinﬂammatory diseases such as multiple sclerosis represent
typical conditions forwhich a better understanding of eMV release
from glia might provide critical insights for innovative treatments.
The well-described glial reactions, including also microglial and
oligodendroglial origin, that take place in multiple sclerosis (Lass-
mann, 2011; Sriram, 2011) as well as the associated alteration of
EAAT expression (Vercellino et al., 2007) both support this pre-
diction. In line with this hypothesis, several studies have pointed
at glial eMV in multiple sclerosis (Scolding et al., 1989; Verderio
et al., 2012). Furthermore, glia-derived eMV might be future tar-
gets in other neurological conditions associated with profound
gliosis and EAAT dysfunction such as stroke or spinal cord injury
(Han et al., 2008; Ketheeswaranathan et al., 2011). Besides the
established neuro-inﬂammatory diseases listed above, eMV con-
stitute a promising ﬁeld of investigation in neurodegenerative
diseases as well, so far mostly explored under the angle of neuronal
eMV (Rajendran et al., 2006; Gomes et al., 2007; Emmanouili-
dou et al., 2010; Saman et al., 2012). Besides, even though we do
not provide direct evidence that such PKC-driven regulation also
occurs in homeostasis, the presence of EAAT in eMV from non-
stimulated cells and explants suggests this possibility. However,
despite the above-mentioned medical potential, signiﬁcant break-
throughs will be obstructed by the persisting lack of consensual
classiﬁcations and deﬁnitions regarding eMVs. In depth investi-
gations about eMV regulations are urgently needed to both shed
some signiﬁcant light on their function in homeostasis, as well as
to convert these insights into credible clinical outcomes.
Altogether, our data on EAAT release in eMV add a new dimen-
sion to the regulation of glutamate transporters in astrogliosis.
This may open new avenues for neurological treatments involving
eMV regulation by PKC. Alternatively, exogenous interventional
strategies using the capacity of eMV to scavenge glutamate may
ultimately provide a way to address pathologies connected with
defects in EAAT function.
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